-+ 0.00%
-+ 0.00%
-+ 0.00%

Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidates

PUBT·08/28/2026 08:48:23
Listen to the news
Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidates
  • Heidelberg Pharma broadened its strategic partnership with Huadong Medicine via a new joint R&D collaboration for next-generation ADCs.
  • Scope covers up to six targets, aiming to add new product candidates to Heidelberg Pharma’s pipeline.
  • Program combines Heidelberg Pharma’s ATAC technology platform and novel toxin payloads with Huadong’s R&D capabilities.
  • Work includes bispecific or multispecific ADCs, with options for dual-payload designs.
  • Ownership of resulting development candidates will be split between partners based on their respective contributions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2390328_en) on August 28, 2026, and is solely responsible for the information contained therein.